Sign up USA
Proactive Investors - Run By Investors For Investors

PhaseRX shares surge as it halves workforce to cut costs

PhaseRx said its restructuring was aimed at preserving its cash resources
health
PhaseRx will delay the development of its lead product candidate

PhaseRx Inc. NASDAQ:PZRX) shares rocketed up more than 80% after the biopharmaceutical company announced it was cutting 10 jobs, representing half of its workforce.

The job cuts include some executive officers as part of a corporate restructuring, which PhaseRx said was aimed at preserving cash resources.

The firm had cash and equivalents of US$8.4mln and a total of 20 employees on 30 June.

PhaseRx also said it would delay the development of its lead product candidate PRX-OTC , a treatment for children with inherited enzyme deficiencies in the liver,

Shares jumped 80.78% to 1.60p each in early US trading, marking a major rebound after falling 43%  in the year to date though Thursday. 

View full PZRX profile View Profile

PhaseRx Timeline

Related Articles

Novogen: Access latest PPT from Proactive's CEO Sessions
April 12 2017
Dr James Garner talked clinical-stage programs with investors.
clinical-trial.jpg
June 30 2017
In all 200 suffers were recruited to the trial and all of them have now past the three month stage.
newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use